Price
No data yet.
Social Signal Score
Analyst Ratings
12 analystsRevenue
$167.09M+4.46%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Martin D. Madaus
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 2,900
- Beta
- 1.47
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 5.08
Financials
Revenue
$167.09M+4.5%Net Income
$6.79M-51.1%EBITDA
$22.84M+5.9%Free Cash Flow
$11.86M-20.7%EPS (diluted)
$0.16-20.0%Shares Outstanding (diluted)
43.47M-37.8%Operating Expenses
$72.30MCash & Debt
$332.68MReturn of Capital
$68.24MRevenue by Segment (annual)
$593.82MDividend per Share
$0.10Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $621.70M | $-166.99M | $-3.70 |
| 2025 | $593.82M | $-55.76M | $-1.22 |
| 2024 | $573.45M | $-164.90M | $-3.09 |
| 2023 | $665.07M | $-14.26M | $-0.22 |
| 2022 | $555.50M | $-428.96M | $-0.15 |
| 2021 | $513.70M | $110.75M | $1.49 |
| 2020 | $388.54M | $64.85M | $0.88 |
| 2019 | $780.85M | $28.82M | $0.14 |
| 2018 | $631.56M | $116.58M | $1.65 |
| 2017 | $527.50M | $62.61M | $0.90 |
| 2016 | $560.32M | $-69.48M | $-1.02 |
| 2015 | $552.71M | $14.22M | $0.21 |
| 2014 | $482.85M | $4.46M | $0.47 |
| 2013 | $422.44M | $-2.21M | $-0.03 |
Valuation
AZTAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+50.00%Social Signal Score
Mentions (7)
- Newsseekingalpha.com·11d ago·Positive
Azenta, Inc. (AZTA) Q4 2026 Earnings Call Transcript Azenta, Inc. ( AZTA ) Q4 2026 Earnings Call November 11, 2026 8:30 AM EST Company Participants Yvonne Perron - Vice President of Financial Planning & Analysis and Investor Relations Martin Madaus - Interim President, CEO & Director William Martin - Senior Vice President & President of Multiomics Lawrence Lin - Executive VP & CFO Conference Call Participants David Saxon - Needham & Company, LLC, Research Division Matthew Stanton - Jefferies LLC…
View source ↗ - Newsprnewswire.com·12d ago·Neutral
…adjusted EBITDA margin expected to expand approximately 200 to 250 basis points year over year BURLINGTON, Mass., Nov. 10, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the fourth quarter and fiscal year ended September 30, 2026.
View source ↗ - Newsseekingalpha.com·19d ago·Positive
Azenta: A Sample Custody Annuity Priced Like A Broken Equipment Vendor Azenta is undervalued, with 30% of its market cap in cash and a strong recurring revenue base overlooked due to capital equipment struggles. Recurring streams now exceed 50% of revenue, and the annuity-like custody and consumables business is masked by temporary hardware margin compression. Leadership transition introduces uncertainty, but the interim CEO's track record and portfolio simplification signal potential for discip
View source ↗ - Newsprnewswire.com·23d ago·Positive
Azenta Announces Strategic Investments to Advance the Next Generation of GENEWIZ Gene Synthesis Capabilities Exclusive licensing agreement with Elegen and acquisition of SynPlexity strengthen gene synthesis capabilities, expand high-throughput discovery workflows, and position GENEWIZ for long-term growth BURLINGTON, Mass., Oct. 30, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced strategic investments to advance the next phase of growth for its GENEWIZ business.
View source ↗ - Newsprnewswire.com·25d ago·Neutral
Azenta Announces Fiscal 2026 Fourth Quarter and Full Year Conference Call and Webcast BURLINGTON, Mass., Oct. 28, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal fourth quarter and full year 2026 earnings which ended on September 30, 2026, on Tuesday, November 10, 2026, after the market closes.
View source ↗ - Newsprnewswire.com·79d ago·Negative
Azenta Receives Full Repayment of $35 Million Vendor Loan Related to Sale of B Medical Systems BURLINGTON, Mass., Sept. 4, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it has received repayment in full, prior to maturity, of the $35 million secured vendor loan extended in connection with the previously announced sale of B Medical Systems S.
View source ↗ - Newsseekingalpha.com·100d ago·Positive
Azenta: Needs To Overcome A Few Hurdles If The Rally Is To Continue AZTA went down for a long time, resulting in a multi-year low in May 2026, but the stock has rallied higher since then. While the stock has doubled in value, there is a chart that suggests to be wary of the rally because it could unwind itself in the near future. The current financial model from AZTA makes a case for being long, but that depends on whether AZTA can hit the targets laid out.
View source ↗
Earnings
Wed, Feb 3(in 2 months)
Consensus estimate $0.10 per share
Typical surprise +10.8% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 10$0.28 vs $0.11beat
- Tue, Aug 4$0.16 vs $0.11beat
- Wed, May 6$-0.04 vs $0.10miss
- Wed, Feb 4$0.09 vs $0.11miss
- Fri, Nov 21$0.21 vs $0.19beat
- Tue, Aug 5$0.19 vs $0.13beat
Estimates and results for AZTA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AZTA officers and directors.
- Bought
- $2.1m
- Sold
- $224k
14 trades
10 trades
- Starr Ephraimbought
- Cornog William Lbought
- Marotta Johnsold
- Pirogova Olgasold
- Zhou Gingersold
- Lin Lawrence Y.bought
- Marotta Johnbought
- Malus Alan Jbought
76 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Cisneroshouse · CA31 · disclosed Apr 8, 2026 (36d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Feb 13, 2026 (29d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Nov 18, 2025 (40d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Apr 11, 2025 (23d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Oct 15, 2023 (30d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Aug 21, 2023 (38d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Jul 11, 2023 (28d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Jan 10, 2022 (38d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Jan 10, 2022 (26d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
